{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:35:40Z","timestamp":1793716540432,"version":"4.6.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["No. 2022YFC2010103"],"award-info":[{"award-number":["No. 2022YFC2010103"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Central health research project","award":["No. 2020ZD10"],"award-info":[{"award-number":["No. 2020ZD10"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07411-4","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T11:39:57Z","timestamp":1763984397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predict disabling severe attacks in neuromyelitis optica spectrum disorders: warning symptoms and innovative machine learning models"],"prefix":"10.1186","volume":"23","author":[{"given":"Weizhe","family":"Zhen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujuan","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dantao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"4","key":"7411_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"15","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med Aug. 2005;15(4):473\u20137. https:\/\/doi.org\/10.1084\/jem.20050304.","journal-title":"J Exp Med Aug"},{"issue":"2","key":"7411_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/wnl.0000000000001729","volume":"14","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis Optica spectrum disorders. Neurology Jul. 2015;14(2):177\u201389. https:\/\/doi.org\/10.1212\/wnl.0000000000001729.","journal-title":"Neurology Jul"},{"issue":"4","key":"7411_CR3","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00415-019-09685-3","volume":"267","author":"W Zhang","year":"2020","unstructured":"Zhang W, Cui L, Zhang Y, et al. Questioning the existence of monophasic neuromyelitis Optica spectrum disorder by defining a novel long-term relapse-free form from a large Chinese population. J Neurol Apr. 2020;267(4):1197\u2013205. https:\/\/doi.org\/10.1007\/s00415-019-09685-3.","journal-title":"J Neurol Apr"},{"issue":"6","key":"7411_CR4","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/ana.26623","volume":"93","author":"HX Yin","year":"2023","unstructured":"Yin HX, Wang YJ, Liu MG, et al. Aquaporin-4 antibody dynamics and relapse risk in seropositive neuromyelitis Optica spectrum disorder treated with immunosuppressants. Ann Neurol Jun. 2023;93(6):1069\u201381. https:\/\/doi.org\/10.1002\/ana.26623.","journal-title":"Ann Neurol Jun"},{"issue":"3","key":"7411_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s13167-018-0143-9","volume":"9","author":"N Borisow","year":"2018","unstructured":"Borisow N, Hellwig K, Paul F. Neuromyelitis Optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies. Epma J Sep. 2018;9(3):249\u201356. https:\/\/doi.org\/10.1007\/s13167-018-0143-9.","journal-title":"Epma J Sep"},{"key":"7411_CR6","doi-asserted-by":"publisher","first-page":"104580","DOI":"10.1016\/j.msard.2023.104580","volume":"71","author":"DR Rice","year":"2023","unstructured":"Rice DR, Holroyd KB, Pua DK, Levy M, Mateen FJ, Bhattacharyya S. Quantifying the economic burden to patients of relapse events from neuromyelitis Optica spectrum disorders: A cross-sectional survey. Mult Scler Relat Disord Mar. 2023;71:104580. https:\/\/doi.org\/10.1016\/j.msard.2023.104580.","journal-title":"Mult Scler Relat Disord Mar"},{"key":"7411_CR7","doi-asserted-by":"publisher","first-page":"102522","DOI":"10.1016\/j.msard.2020.102522","volume":"46","author":"X Ma","year":"2020","unstructured":"Ma X, Kermode AG, Hu X, Qiu W. Risk of relapse in patients with neuromyelitis Optica spectrum disorder: recognition and preventive strategy. Mult Scler Relat Disord Nov. 2020;46:102522. https:\/\/doi.org\/10.1016\/j.msard.2020.102522.","journal-title":"Mult Scler Relat Disord Nov"},{"issue":"3","key":"7411_CR8","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","volume":"71","author":"MA Mealy","year":"2014","unstructured":"Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol Mar. 2014;71(3):324\u201330. https:\/\/doi.org\/10.1001\/jamaneurol.2013.5699.","journal-title":"JAMA Neurol Mar"},{"key":"7411_CR9","doi-asserted-by":"publisher","unstructured":"Palace J, Lin DY, Zeng D, et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain. 2019;142(5):1310\u20131323. https:\/\/doi.org\/10.1093\/brain\/awz054.","DOI":"10.1093\/brain\/awz054"},{"issue":"6","key":"7411_CR10","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/s1474-4422(13)70076-0","volume":"12","author":"SJ Pittock","year":"2013","unstructured":"Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis Optica spectrum disorders: an open-label pilot study. Lancet Neurol Jun. 2013;12(6):554\u201362. https:\/\/doi.org\/10.1016\/s1474-4422(13)70076-0.","journal-title":"Lancet Neurol Jun"},{"issue":"1","key":"7411_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jnnp-2021-327206","volume":"93","author":"V Camera","year":"2022","unstructured":"Camera V, Messina S, Elhadd KT, et al. Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis Optica spectrum disorders. J Neurol Neurosurg Psychiatry Jan. 2022;93(1):101\u201311. https:\/\/doi.org\/10.1136\/jnnp-2021-327206.","journal-title":"J Neurol Neurosurg Psychiatry Jan"},{"issue":"10","key":"7411_CR12","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2023.2974","volume":"1","author":"Y Fu","year":"2023","unstructured":"Fu Y, Bi J, Yan Y, et al. Rapid Immunodot AQP4 assay for neuromyelitis Optica spectrum disorder. JAMA Neurol Oct. 2023;1(10):1105\u201312. https:\/\/doi.org\/10.1001\/jamaneurol.2023.2974.","journal-title":"JAMA Neurol Oct"},{"issue":"8003","key":"7411_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41586-024-07079-8","volume":"627","author":"AM Afzali","year":"2024","unstructured":"Afzali AM, Nirschl L, Sie C, et al. B cells orchestrate tolerance to the neuromyelitis Optica autoantigen AQP4. Nature Mar. 2024;627(8003):407\u201315. https:\/\/doi.org\/10.1038\/s41586-024-07079-8.","journal-title":"Nature Mar"},{"issue":"6","key":"7411_CR14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/s1474-4422(24)00115-7","volume":"23","author":"C Zhang","year":"2024","unstructured":"Zhang C, Shi FD. Targeting B cells in neuromyelitis Optica spectrum disorder. Lancet Neurol Jun. 2024;23(6):549\u201350. https:\/\/doi.org\/10.1016\/s1474-4422(24)00115-7.","journal-title":"Lancet Neurol Jun"},{"issue":"4","key":"7411_CR15","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/brain\/awad373","volume":"4","author":"G Arellano","year":"2024","unstructured":"Arellano G, Loda E, Chen Y, et al. Interferon-\u03b3 controls Aquaporin 4-specific Th17 and B cells in neuromyelitis Optica spectrum disorder. Brain Apr. 2024;4(4):1344\u201361. https:\/\/doi.org\/10.1093\/brain\/awad373.","journal-title":"Brain Apr"},{"key":"7411_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3389\/fimmu.2019.00201","volume":"10","author":"S H\u00e4usser-Kinzel","year":"2019","unstructured":"H\u00e4usser-Kinzel S, Weber MS. The role of B cells and antibodies in multiple Sclerosis, neuromyelitis Optica, and related disorders. Front Immunol. 2019;10:201. https:\/\/doi.org\/10.3389\/fimmu.2019.00201.","journal-title":"Front Immunol"},{"issue":"5","key":"7411_CR17","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ana.26067","volume":"89","author":"O Aktas","year":"2021","unstructured":"Aktas O, Smith MA, Rees WA, et al. Serum glial fibrillary acidic protein: A neuromyelitis Optica spectrum disorder biomarker. Ann Neurol May. 2021;89(5):895\u2013910. https:\/\/doi.org\/10.1002\/ana.26067.","journal-title":"Ann Neurol May"},{"issue":"1","key":"7411_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12974-021-02138-7","volume":"1","author":"P Schindler","year":"2021","unstructured":"Schindler P, Grittner U, Oechtering J, et al. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis Optica spectrum disorder. J Neuroinflammation May. 2021;1(1):105. https:\/\/doi.org\/10.1186\/s12974-021-02138-7.","journal-title":"J Neuroinflammation May"},{"issue":"1","key":"7411_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12974-022-02450-w","volume":"12","author":"JW Hyun","year":"2022","unstructured":"Hyun JW, Kim Y, Kim KH, et al. CSF GFAP levels in double seronegative neuromyelitis Optica spectrum disorder: no evidence of astrocyte damage. J Neuroinflammation Apr. 2022;12(1):86. https:\/\/doi.org\/10.1186\/s12974-022-02450-w.","journal-title":"J Neuroinflammation Apr"},{"issue":"15","key":"7411_CR20","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1212\/wnl.0000000000000317","volume":"82","author":"M Araki","year":"2014","unstructured":"Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody Tocilizumab in neuromyelitis optica: a pilot study. Neurology Apr 15. 2014;82(15):1302\u20136. https:\/\/doi.org\/10.1212\/wnl.0000000000000317.","journal-title":"Neurology Apr 15"},{"key":"7411_CR21","doi-asserted-by":"publisher","unstructured":"Matsuoka T, Araki M, Lin Y, et al. Long-term effects of IL-6 receptor blockade therapy on regulatory lymphocytes and neutrophils in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2024;11(1). https:\/\/doi.org\/10.1212\/nxi.0000000000200173.","DOI":"10.1212\/nxi.0000000000200173"},{"issue":"1","key":"7411_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","volume":"22","author":"S Jarius","year":"2020","unstructured":"Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis Optica. Nat Rev Dis Primers Oct. 2020;22(1):85. https:\/\/doi.org\/10.1038\/s41572-020-0214-9.","journal-title":"Nat Rev Dis Primers Oct"},{"issue":"12","key":"7411_CR23","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","volume":"17","author":"SJ Pittock","year":"2021","unstructured":"Pittock SJ, Zekeridou A, Weinshenker BG. Hope for patients with neuromyelitis Optica spectrum disorders - from mechanisms to trials. Nat Rev Neurol Dec. 2021;17(12):759\u201373. https:\/\/doi.org\/10.1038\/s41582-021-00568-8.","journal-title":"Nat Rev Neurol Dec"},{"issue":"6","key":"7411_CR24","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1007\/s00415-023-11641-1","volume":"270","author":"Z Yin","year":"2023","unstructured":"Yin Z, Qiu Y, Duan A, et al. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis Optica spectrum disorder: a bayesian network meta-analysis. J Neurol Jun. 2023;270(6):2950\u201363. https:\/\/doi.org\/10.1007\/s00415-023-11641-1.","journal-title":"J Neurol Jun"},{"issue":"22","key":"7411_CR25","doi-asserted-by":"publisher","first-page":"e2504","DOI":"10.1212\/wnl.0000000000201260","volume":"29","author":"P Barreras","year":"2022","unstructured":"Barreras P, Vasileiou ES, Filippatou AG, et al. Long-term effectiveness and safety of rituximab in neuromyelitis Optica spectrum disorder and MOG antibody disease. Neurology Nov. 2022;29(22):e2504\u201316. https:\/\/doi.org\/10.1212\/wnl.0000000000201260.","journal-title":"Neurology Nov"},{"key":"7411_CR26","doi-asserted-by":"publisher","first-page":"105600","DOI":"10.1016\/j.msard.2024.105600","volume":"86","author":"L Cui","year":"2024","unstructured":"Cui L, Jiao J, Zhang Y, et al. FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis Optica spectrum disorder. Mult Scler Relat Disord Jun. 2024;86:105600. https:\/\/doi.org\/10.1016\/j.msard.2024.105600.","journal-title":"Mult Scler Relat Disord Jun"},{"issue":"9","key":"7411_CR27","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/jnnp-2022-330412","volume":"94","author":"O Aktas","year":"2023","unstructured":"Aktas O, Hartung HP, Smith MA, et al. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis Optica spectrum disorder. J Neurol Neurosurg Psychiatry Sep. 2023;94(9):757\u201368. https:\/\/doi.org\/10.1136\/jnnp-2022-330412.","journal-title":"J Neurol Neurosurg Psychiatry Sep"},{"key":"7411_CR28","doi-asserted-by":"publisher","first-page":"720907","DOI":"10.3389\/fimmu.2021.720907","volume":"12","author":"J Wang","year":"2021","unstructured":"Wang J, Cui C, Lu Y, et al. Therapeutic response and possible biomarkers in acute attacks of neuromyelitis Optica spectrum disorders: A prospective observational study. Front Immunol. 2021;12:720907. https:\/\/doi.org\/10.3389\/fimmu.2021.720907.","journal-title":"Front Immunol"},{"issue":"11","key":"7411_CR29","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/acn3.646","volume":"5","author":"L Amezcua","year":"2018","unstructured":"Amezcua L, Beecham AH, Delgado SR, et al. Native ancestry is associated with optic neuritis and age of onset in Hispanics with multiple sclerosis. Ann Clin Transl Neurol Nov. 2018;5(11):1362\u201371. https:\/\/doi.org\/10.1002\/acn3.646.","journal-title":"Ann Clin Transl Neurol Nov"},{"issue":"7","key":"7411_CR30","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s10072-019-03830-6","volume":"40","author":"P Annunziata","year":"2019","unstructured":"Annunziata P, Masi G, Cioni C, et al. Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study. Neurol Sci Jul. 2019;40(7):1383\u201391. https:\/\/doi.org\/10.1007\/s10072-019-03830-6.","journal-title":"Neurol Sci Jul"},{"key":"7411_CR31","doi-asserted-by":"publisher","unstructured":"M\u00fcller J, Sinnecker T, Wendebourg MJ, et al. Choroid plexus volume in multiple sclerosis vs neuromyelitis optica spectrum disorder: a retrospective, cross-sectional analysis. Neurol Neuroimmunol Neuroinflamm. 2022;9(3). https:\/\/doi.org\/10.1212\/nxi.0000000000001147.","DOI":"10.1212\/nxi.0000000000001147"},{"key":"7411_CR32","doi-asserted-by":"publisher","first-page":"599042","DOI":"10.3389\/fneur.2020.599042","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim H, Lee Y, Kim YH, et al. Deep Learning-Based method to differentiate neuromyelitis Optica spectrum disorder from multiple sclerosis. Front Neurol. 2020;11:599042. https:\/\/doi.org\/10.3389\/fneur.2020.599042.","journal-title":"Front Neurol"},{"key":"7411_CR33","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2147\/jir.S442532","volume":"17","author":"W Xiang","year":"2024","unstructured":"Xiang W, Wu Y, Li H, et al. Serum albumin level can predict immunotherapy response of neuromyelitis Optica spectrum disorders in the acute phase. J Inflamm Res. 2024;17:909\u201317. https:\/\/doi.org\/10.2147\/jir.S442532.","journal-title":"J Inflamm Res"},{"key":"7411_CR34","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3389\/fneur.2018.00648","volume":"9","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zhu M, Liu C, et al. Blood brain barrier permeability could be a biomarker to predict severity of neuromyelitis Optica spectrum disorders: A retrospective analysis. Front Neurol. 2018;9:648. https:\/\/doi.org\/10.3389\/fneur.2018.00648.","journal-title":"Front Neurol"},{"key":"7411_CR35","doi-asserted-by":"publisher","first-page":"973163","DOI":"10.3389\/fneur.2022.973163","volume":"13","author":"L Han","year":"2022","unstructured":"Han L, Hong P, Wan Y, et al. Neuromyelitis Optica spectrum disorder in Western China impacts employment and increases financial burden in women. Front Neurol. 2022;13:973163. https:\/\/doi.org\/10.3389\/fneur.2022.973163.","journal-title":"Front Neurol"},{"issue":"2","key":"7411_CR36","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s40120-021-00253-4","volume":"10","author":"M Royston","year":"2021","unstructured":"Royston M, Kielhorn A, Weycker D, et al. Neuromyelitis Optica spectrum disorder: clinical burden and cost of relapses and Disease-Related care in US clinical practice. Neurol Ther Dec. 2021;10(2):767\u201383. https:\/\/doi.org\/10.1007\/s40120-021-00253-4.","journal-title":"Neurol Ther Dec"},{"key":"7411_CR37","doi-asserted-by":"publisher","first-page":"101965","DOI":"10.1016\/j.msard.2020.101965","volume":"40","author":"S Asseyer","year":"2020","unstructured":"Asseyer S, Hamblin J, Messina S, et al. Prodromal headache in MOG-antibody positive optic neuritis. Mult Scler Relat Disord May. 2020;40:101965. https:\/\/doi.org\/10.1016\/j.msard.2020.101965.","journal-title":"Mult Scler Relat Disord May"},{"issue":"4","key":"7411_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11916-017-0620-1","volume":"21","author":"A Masters-Israilov","year":"2017","unstructured":"Masters-Israilov A, Robbins MS. Headache in neuromyelitis Optica. Curr Pain Headache Rep Apr. 2017;21(4):20. https:\/\/doi.org\/10.1007\/s11916-017-0620-1.","journal-title":"Curr Pain Headache Rep Apr"},{"issue":"9","key":"7411_CR39","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nrneurol.2014.129","volume":"10","author":"M Bradl","year":"2014","unstructured":"Bradl M, Kanamori Y, Nakashima I, et al. Pain in neuromyelitis optica\u2013prevalence, pathogenesis and therapy. Nat Rev Neurol Sep. 2014;10(9):529\u201336. https:\/\/doi.org\/10.1038\/nrneurol.2014.129.","journal-title":"Nat Rev Neurol Sep"},{"issue":"3","key":"7411_CR40","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s13311-021-01055-0","volume":"18","author":"L Cacciaguerra","year":"2021","unstructured":"Cacciaguerra L, Tortorella P, Rocca MA, Filippi M. Targeting neuromyelitis Optica pathogenesis: results from randomized controlled trials of biologics. Neurotherapeutics Jul. 2021;18(3):1623\u201336. https:\/\/doi.org\/10.1007\/s13311-021-01055-0.","journal-title":"Neurotherapeutics Jul"},{"issue":"5","key":"7411_CR41","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00281-022-00941-9","volume":"44","author":"N Chihara","year":"2022","unstructured":"Chihara N, Yamamura T. Immuno-pathogenesis of neuromyelitis Optica and emerging therapies. Semin Immunopathol Sep. 2022;44(5):599\u2013610. https:\/\/doi.org\/10.1007\/s00281-022-00941-9.","journal-title":"Semin Immunopathol Sep"},{"issue":"1","key":"7411_CR42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00401-017-1734-6","volume":"134","author":"L Tradtrantip","year":"2017","unstructured":"Tradtrantip L, Yao X, Su T, Smith AJ, Verkman AS. Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis Optica. Acta Neuropathol Jul. 2017;134(1):35\u201344. https:\/\/doi.org\/10.1007\/s00401-017-1734-6.","journal-title":"Acta Neuropathol Jul"},{"issue":"1","key":"7411_CR43","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","volume":"16","author":"E Carnero Contentti","year":"2021","unstructured":"Carnero Contentti E, Correale J. Neuromyelitis Optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflammation Sep. 2021;16(1):208. https:\/\/doi.org\/10.1186\/s12974-021-02249-1.","journal-title":"J Neuroinflammation Sep"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07411-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07411-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07411-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T11:39:58Z","timestamp":1763984398000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07411-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7411"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07411-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of China-Japan Friendship Hospital (Ethics ID: Approval No. 2020\u201331-Y06-32), and the need for informed consent was waived by the committee because of the study\u2019s retrospective nature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1342"}}